Sutro Biopharma, Inc.
STRO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $0 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -84.8% | 266.4% | 17.5% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -459.6% | 1.7% | -261.9% | -402% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -586.6% | -18% | -436.6% | -489.2% |
| EPS Diluted | -6.7 | -1.4 | -9.1 | -8.8 |
| % Growth | -378.6% | 84.6% | -3.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |